61674-96-2

Upstream product

• 3587-60-8 Benzyloxymethyl chloride 
• 3814-41-3 3-methylbut-2-en-2-yl acetate 
• 563-80-4 3-methyl-butan-2-one 
• 1823-90-1 4-hydroxy-3,3-dimethyl-butan-2-one 
• 100-39-0 benzyl bromide 

Downstream Products

• 566927-83-1 (7S,9S,10S)-1-Benzyloxy-5-hydroxy-9-methoxy-10-methoxymethoxy-2,2-dimethyl-7-triethylsilanyloxy-dodec-11-en-3-one 
• 880343-24-8 4-benzyloxy-3,3-dimethyl-2-oxo-butyraldehyde 
• 566927-62-6 (R)-6-(2-Benzyloxy-1,1-dimethyl-ethyl)-2-((2S,3S)-2-methoxy-3-methoxymethoxy-pent-4-enyl)-2,3-dihydro-pyran-4-one 
• 566927-63-7 (2S,4S)-6-(2-Benzyloxy-1,1-dimethyl-ethyl)-2-((2S,3S)-2-methoxy-3-methoxymethoxy-pent-4-enyl)-3,4-dihydro-2H-pyran-4-ol 
• 749260-72-8 (2S,3S,4S,6S)-2-(2-Benzyloxy-1,1-dimethyl-ethyl)-2,4-dimethoxy-6-((2S,3S)-2-methoxy-3-methoxymethoxy-pent-4-enyl)-tetrahydro-pyran-3-ol 
• 566927-64-8 (2S,3S,4S,6S)-2-(2-Benzyloxy-1,1-dimethyl-ethyl)-2-methoxy-6-((2S,3S)-2-methoxy-3-methoxymethoxy-pent-4-enyl)-tetrahydro-pyran-3,4-diol 
• 566927-61-5 (7R,9S,10S)-1-Benzyloxy-9-methoxy-10-methoxymethoxy-2,2-dimethyl-7-triethylsilanyloxy-dodec-11-ene-3,5-dione 
• 566927-65-9 [(2S,3S,4S,6R)-2-(2-Benzyloxy-1,1-dimethyl-ethyl)-2,4-dimethoxy-6-((2S,3S)-2-methoxy-3-methoxymethoxy-pent-4-enyl)-tetrahydro-pyran-3-yloxy]-triethyl-silane 
• 566927-66-0 (2R,3S)-4-[(2R,4S,5S,6S)-6-(2-Benzyloxy-1,1-dimethyl-ethyl)-4,6-dimethoxy-5-triethylsilanyloxy-tetrahydro-pyran-2-yl]-3-methoxy-2-methoxymethoxy-butyric acid methyl ester 
• 749260-95-5 C₂₅H₄₀O₄Si 

Relevant academic research and scientific papers

Polycyclic compound and application thereof as antiviral drug

The invention relates to a polycyclic compound and application of the polycyclic compound as an antiviral drug, in particular to a compound shown in a formula (I) or pharmaceutically acceptable salts,solvates, geometric isomers, stereoisomers, tautomers and any mixtures thereof. The compound shown in the formula (I) or the pharmaceutically acceptable salts, solvates and medicinal compositions thereof can be used for treating and/or preventing hepatitis B virus infection, and particularly, the compound, a TLR7 inhibitor and nucleoside medicines can be used as medicinal compositions for curinghepatitis B.

FUSED TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS

The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.

COMBINATION THERAPY OF AN HBSAG INHIBITOR AND AN INTERFERON

The present invention is directed to compositions and methods for treating hepatitis B virus infection. In particular, the present invention is directed to a combination therapy comprising administration of an HBsAg inhibitor and an interferon for use in the treatment or prophylaxis of chronic Hepatitis B virus infections.

COMBINATION THERAPY OF AN HBSAG INHIBITOR AND AN HBV CAPSID ASSEMBLY INHIBITOR

The present invention is directed to compositions and methods for treating hepatitis B virus infection. In particular, the present invention is directed to a combination therapy comprising administration of an HBs Ag inhibitor and an HBV capsid assembly inhibitor for use in the treatment or prophylaxis of chronic hepatitis B infected patients.

NOVEL 6,7-DIHYDROBENZO[A]QUINOLIZIN-2-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

The invention provides novel compounds having the general formula (I) wherein R1 to R6, W and X are as described herein and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.